Experimental drug shows promise for stiff heart disease
NCT ID NCT05442047
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental drug called NNC6019-0001 in 105 people with transthyretin amyloid cardiomyopathy, a condition where abnormal proteins build up in the heart, causing heart failure. Participants received either the drug or a placebo by infusion every 4 weeks for about 64 weeks. The goal was to see if the drug could improve walking distance and reduce markers of heart strain.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NNC6019-0001 (an experimental drug given by infusion)
What this could lead to
If it works, this could point toward a new treatment to manage heart failure symptoms in people with ATTR amyloid cardiomyopathy.
What could go wrong
This is an early Phase 2 trial with only 105 participants, so results may not apply to everyone. The drug is still experimental and not yet approved.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ap-Hp-Hopital Henri Mondor
Créteil, 94000, France
-
Cedars-Sinai Medical Center_Los Angeles
Beverly Hills, California, 90211, United States
-
Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil
Toulouse, 31059, France
-
Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil-1
Toulouse Cedex 9 TSA 50032, 31059, France
-
Centro per lo Studio e la Cura delle Amiloidosi Sistemiche Fondazione IRCCS Policlinico San Matteo
Pavia, PV, 27100, Italy
-
Ctr for Cardiovascular Innovation
Vancouver, British Columbia, V5Z 1M9, Canada
-
Fondazione Toscana Gabriele Monasterio - Dipartimento Cardiotoracico - UOC Cardiologia e Medicina Cardiovascolare
Pisa, Pi, 56124, Italy
-
Hiroshima University hospital, Cardiovascular Medicine
Hiroshima, 734-8551, Japan
-
Hiroshima University hospital_Cardiovascular Medicine
Hiroshima, 734-8551, Japan
-
Hospital Universitario Puerta de Hierro Majadahonda
Majadahonda, Madrid, 28222, Spain
-
Hospital Universitario Puerta de Hierro Majadahonda
Madrid, 28222, Spain
-
Hospital da Senhora da Oliveira - Guimarães
Guimarães, 4835-044, Portugal
-
Hospital of the University of Occupational and Environmental Health
Fukuoka, 807-8556, Japan
-
Hospital of the University of Occupational and Environmental Health, Cardiology, Nephrology
Fukuoka, 807-8556, Japan
-
II. interni klinika VFN - Kardiologie a angiologie
Prague, 12808, Czechia
-
Kumamoto University Hospital, Cardiovascular Medicine
Kumamoto-shi, Kumamoto, 860-8556, Japan
-
LMU Klinikum München Klinik und Poliklinik 1
München, 81377, Germany
-
Mayo Clinic Arizona
Phoenix, Arizona, 85054, United States
-
Mayo Clinic Jacksonville
Jacksonville, Florida, 32224, United States
-
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States
-
NW Univ-Bluhm Cardiovasc Inst
Evanston, Illinois, 60208, United States
-
Nagasaki University Hospital, Cardiovascular Medicine
Nagasaki, 852-8501, Japan
-
Okayama University Hospital_Cardiovascular Medicine
Okayama-shi, Okayama, 700-8558, Japan
-
Oregon Hlth Sci Univ-Portland
Portland, Oregon, 97239-4501, United States
-
Shinshu University Hospital, Department of Neurology
Nagano, 390-8621, Japan
-
Stanford Hlth Cre-Boswell Clin
Stanford, California, 94305, United States
-
ULS De Tras-Os-Montes E Alto Douro E.P.E. - Unidade Hospitalar de Vila Real
Vila Real, 5000-508, Portugal
-
ULS Do Alto Ave, E.P.E. - Hospital Senhora da Oliveira - Guimarães
Guimarães, 4835-044, Portugal
-
UMC Groningen
Groningen, 9713 GZ, Netherlands
-
UMC Groningen afdeling Cardiologie
Groningen, 9713 GZ, Netherlands
-
Unidade Local de Saude do Alto Ave, E.P.E.
Guimarães, 4835-044, Portugal
-
UniklinikHeidelberg - Innere Med. III - Kardiologie, Angiologie, Pneumologie
Heidelberg, 69120, Germany
-
Univ of MD Schl of Med
Baltimore, Maryland, 21201, United States
-
Universitair Medisch Centrum Utrecht
Utrecht, 3584 CX, Netherlands
-
Universitatsklinikum Wurzburg AöR
Würzburg, 97078, Germany
-
Universitatsklinikum Würzburg - Zentrum für Herzinsuffizienz
Würzburg, 97078, Germany
-
University of Calgary_Cardiology
Calgary, Alberta, T2N 4Z6, Canada
-
University of Maryland School of Medicine
Baltimore, Maryland, 21201, United States
-
Universitätsklinikum Münster - Klinik für Kardiologie I
Münster, 48149, Germany